FI115035B - In vivo -avbildning genom att använda peptidderivat - Google Patents

In vivo -avbildning genom att använda peptidderivat Download PDF

Info

Publication number
FI115035B
FI115035B FI20030664A FI20030664A FI115035B FI 115035 B FI115035 B FI 115035B FI 20030664 A FI20030664 A FI 20030664A FI 20030664 A FI20030664 A FI 20030664A FI 115035 B FI115035 B FI 115035B
Authority
FI
Finland
Prior art keywords
peptide
llg
stamp
imaging
targeting
Prior art date
Application number
FI20030664A
Other languages
English (en)
Finnish (fi)
Other versions
FI20030664A0 (sv
FI20030664A (sv
Inventor
Kalevi Kairemo
Sami Kaukinen
Heli Valtanen
Original Assignee
Ctt Cancer Targeting Tech Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ctt Cancer Targeting Tech Oy filed Critical Ctt Cancer Targeting Tech Oy
Priority to FI20030664A priority Critical patent/FI115035B/sv
Publication of FI20030664A0 publication Critical patent/FI20030664A0/sv
Priority to JP2006505648A priority patent/JP2006525289A/ja
Priority to EP04730885A priority patent/EP1620135A1/en
Priority to KR1020057020866A priority patent/KR20060025137A/ko
Priority to US10/554,996 priority patent/US20070072251A1/en
Priority to PCT/FI2004/000265 priority patent/WO2004096291A1/en
Publication of FI20030664A publication Critical patent/FI20030664A/sv
Application granted granted Critical
Publication of FI115035B publication Critical patent/FI115035B/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Claims (10)

1. Användning av en sädan peptid, som innehäller strukturen 20 i ; CXCXLLGCC, i t 1 . · · ·, väri X är en vilken som heist aminosyrarest, i tumör targeting. • * t *» t . * · ’, 25
2. Använding av en sädan peptid, som innehäller strukturen • · · .:· CXCXLLGCC, t \ t a » · < > » , v, väri X är en vilken som heist aminosyrarest, för diagnostiska ändamäl. 30 > * .
, 3. Användning enligt patentkravet 2, väri peptiden enligt patentkravet 2 fogas tili en radio- ! aktiv stämpel, en magnetisk partikel eller en fluorescerande stämpel, för användande som » i · avbildningsmedel. π 115035
4. Användning av en sadan peptid, som innehäller strukturen CPCFLLGCC, i tumör targeting. 5
5. Användning av en sadan peptid, som innehäller strukturen CPCFLLGCC, för diagnostiska ändamäl. 10
6. Användning enligt patentkrav 5, väri den i patentkravet 5 definierade peptiden fogas tili en radioaktiv stämpel, en magnetisk partikel eller en fluorescerande stämpel, för använ-dande som avbildningsmedel.
7. Användning enligt patentkravet 1 eller 4, väri peptiden används som medel för targeting av cytostater i liposomer.
8. Användning enligt nägot av de ovan anförda patentkraven, väri peptiden har modiferats med PEG-molekylen. 20 *
9. Förpackning för avbildning av tumörceller i en patient, vilken förpackning innehäller en komposition, som innehäller ätminstone en sädan peptidförening, som väljs ur gruppen av _. , _ peptider med strukturen i i t i i t • » */>·, 25 CXCXLLGCC, a t (ta ,:. väri X är en vilken som heist aminosyrarest, kopplad tili en detekterbar stämpel. > »
10. Förpackningen enligt patentkravet 9, väri den detekterbara stämpeln är en radioaktiv , 30 stämpel, en magnetisk partikel eller en fluorescerande stämpel. » » a » > ! t
FI20030664A 2003-05-02 2003-05-02 In vivo -avbildning genom att använda peptidderivat FI115035B (sv)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FI20030664A FI115035B (sv) 2003-05-02 2003-05-02 In vivo -avbildning genom att använda peptidderivat
JP2006505648A JP2006525289A (ja) 2003-05-02 2004-05-03 ペプチド誘導体を用いたｉｎｖｉｖｏ画像化方法
EP04730885A EP1620135A1 (en) 2003-05-02 2004-05-03 In vivo imaging using peptide derivatives
KR1020057020866A KR20060025137A (ko) 2003-05-02 2004-05-03 펩티드 유도체를 이용한 생체 내 영상화
US10/554,996 US20070072251A1 (en) 2003-05-02 2004-05-03 In vivo imaging using peptide derivatives
PCT/FI2004/000265 WO2004096291A1 (en) 2003-05-02 2004-05-03 In vivo imaging using peptide derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20030664A FI115035B (sv) 2003-05-02 2003-05-02 In vivo -avbildning genom att använda peptidderivat
FI20030664 2003-05-02

Publications (3)

Publication Number Publication Date
FI20030664A0 FI20030664A0 (sv) 2003-05-02
FI20030664A FI20030664A (sv) 2004-11-03
FI115035B true FI115035B (sv) 2005-02-28

Family

ID=8566059

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20030664A FI115035B (sv) 2003-05-02 2003-05-02 In vivo -avbildning genom att använda peptidderivat

Country Status (6)

Country Link
US (1) US20070072251A1 (sv)
EP (1) EP1620135A1 (sv)
JP (1) JP2006525289A (sv)
KR (1) KR20060025137A (sv)
FI (1) FI115035B (sv)
WO (1) WO2004096291A1 (sv)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008526973A (ja) * 2005-01-12 2008-07-24 プロテオノヴァ、 インコーポレイテッド 標的治療薬を作製する方法
JP4881327B2 (ja) * 2006-01-31 2012-02-22 大鵬薬品工業株式会社 抗腫瘍活性物質のリポソーム製剤
US20120055055A1 (en) 2010-09-02 2012-03-08 Illumin8 Outdoor Media, LLC Systems and Method for Outdoor Media Signage
CN102147410A (zh) * 2010-12-24 2011-08-10 吉林大学 整合素αVβ3检测试剂盒及其制备方法
KR101467676B1 (ko) * 2013-04-12 2014-12-04 울산대학교 산학협력단 암 표적용 펩타이드 및 이의 의학적 용도
WO2018102762A1 (en) 2016-12-02 2018-06-07 Avelas Biosciences, Inc. Nerve labeling compositions and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI114710B (sv) * 2001-03-12 2004-12-15 Ctt Cancer Targeting Tech Oy Nya peptidligander av leukocytintegriner
FI113840B (sv) * 2001-03-26 2004-06-30 Ctt Cancer Targeting Tech Oy Användning av matris-metalloproteinasinhibitorer vid inriktning av liposomer

Also Published As

Publication number Publication date
KR20060025137A (ko) 2006-03-20
EP1620135A1 (en) 2006-02-01
FI20030664A0 (sv) 2003-05-02
JP2006525289A (ja) 2006-11-09
FI20030664A (sv) 2004-11-03
US20070072251A1 (en) 2007-03-29
WO2004096291A1 (en) 2004-11-11

Similar Documents

Publication Publication Date Title
Chen et al. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor αvβ3-integrin expression
Chen et al. Integrin αβ3-targeted imaging of lung cancer
Britz-Cunningham et al. Molecular targeting with radionuclides: state of the science
US5403574A (en) Evaluation and treatment of the multidrug resistance phenotype
EP0670736B1 (en) Labelled interleukin-8 and medical uses thereof
Fani et al. Radiolabeled bicyclic somatostatin-based analogs: a novel class of potential radiotracers for SPECT/PET of neuroendocrine tumors
Guo et al. Cu-64-labeled lactam bridge-cyclized α-MSH peptides for PET imaging of melanoma
CN101203249A (zh) 多（肽）作为螯合剂：制造方法和用途
Gandomkar et al. Clinical evaluation of antimicrobial peptide [99mTc/Tricine/HYNIC0] ubiquicidin 29–41 as a human-specific infection imaging agent
Shen et al. Radiation dosimetry of 131 I-chlorotoxin for targeted radiotherapy in glioma-bearing mice
KR20190009330A (ko) Pet-영상화 면역조정제
BR112012001260B1 (pt) Conjugados de épsilon-polilisina, seu uso, conjugado de macromolécula, e kit
BRPI1006246A2 (pt) &#34;kit para imagem médica marcada e/ou terapias, sonda efetora e método&#34;
JPH08502075A (ja) 標識された単球走化性因子タンパク質材料およびその医学的使用
Goins et al. The use of scintigraphic imaging as a tool in the development of liposome formulations
Miao et al. Reducing renal uptake of 90Y-and 177Lu-labeled alpha-melanocyte stimulating hormone peptide analogues
EP4076534A1 (de) Smart-drug-delivery-system und pharmazeutisches kit für duale nuklearmedizinisch-cytotoxische theranostik
FI115035B (sv) In vivo -avbildning genom att använda peptidderivat
US11052163B2 (en) Homing agents
JP5085824B2 (ja) 低酸素の検出のために有用な化合物の製造
de Murphy et al. 99mTc-glucarate for detection of isoproterenol-induced myocardial infarction in rats
Prasanphanich et al. The effects of linking substituents on the in vivo behavior of site-directed, peptide-based, diagnostic radiopharmaceuticals
JP3717402B2 (ja) 映像化する方法および組成物
Ogawa et al. Astatine-211-labeled aza-vesamicol derivatives as sigma receptor ligands for targeted alpha therapy
Kondo et al. Radioiodinated bicyclic RGD peptide for imaging integrin αvβ3 in cancers

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 115035

Country of ref document: FI